🔬ResearchExperimental Blood Cancer Immunotherapy Shows Survival Benefit in Late-Stage Trial
Sellas Life Sciences announced that its experimental immunotherapy, galinpepimut-S, met its primary endpoint in a Phase 3 trial by lowering the risk of death in acute mye…